TYVYT (Sintilimab Injection) ORIENT-2 Study Met its Primary Endpoint of Overall Survival in the Second-Line Treatment of Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinom

Disclaimer: |
1. This indication is still under clinical trial, which hasn't been approved in China. |
